Ciraparantag acetate
Based on 1 Customer Validation
Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.0%
- CAS 番号: 1644388-83-9
- 分子式: C22H48N12O2.xC2H4O2
-
保管条件:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-50903
RivaroxabanFactor Xa Inhibitor -
HY-10264
EdoxabanFXa Inhibitor -
HY-B0597
Fondaparinux sodiumFactor Xa Inhibitor -
HY-50903R
Rivaroxaban (Standard)Factor Xa Inhibitor -
HY-10268
BetrixabanFactor Xa Inhibitor -
HY-B0385
Gabexate mesylateProteasome Inhibitor -
HY-70035
OtamixabanFactor Xa Inhibitor -
HY-10264R
Edoxaban (Standard)FXa Inhibitor -
HY-10264A
Edoxaban tosylateFXa Inhibitor -
HY-10267
EribaxabanFXa Inhibitor -
HY-10268R
Betrixaban (Standard)Factor Xa Inhibitor -
HY-10268A
Betrixaban maleateFactor Xa Inhibitor
生物活性
製品説明
体外実験
Ciraparantag acetate is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge–charge interactions[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1644388-83-9
-
性状 Solid
-
分子式 C22H48N12O2.xC2H4O2
-
Color White to off-white
-
SMILES
O=C(NCCCN1CCN(CCCNC([C@@H](N)CCCNC(N)=N)=O)CC1)[C@@H](N)CCCNC(N)=N.CC(O)=O.[x]
-
別名
PER977 acetate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度
体外:
H2O : 125 mg/mL (Need ultrasonic)
純度とドキュメンテーション
-
データシート (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25. [Content Brief] [Content Brief]
[2]. Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. [Content Brief] [Content Brief]
[3]. Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. [Content Brief] [Content Brief]
[4]. Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158. [Content Brief] [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Ciraparantag acetate 関連分類
HY-18660B 関連分類
Powered by Bioz